Dicon

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Dicon

Quick Facts

Property Description
Primary Active Ingredient Diacerein (INN)
Pharmacological Class Anthraquinone Derivative / Anti-rheumatic Agent
Primary Use Symptomatic treatment of Osteoarthritis (OA)
Action Profile Slow-acting (SADOA)
Prescription Status Prescription Only (Rx)

Dicon is a prescribed medication whose name generally refers to products containing the active substance diacerein. Diacerein is classified chemically as an anthraquinone derivative and is metabolized into its active form, rhein. It belongs to the therapeutic class of anti-rheumatic and anti-inflammatory agents.

Its primary medical purpose is the symptomatic long-term treatment of osteoarthritis (OA) affecting the hip and knee joints. Diacerein is distinct because it is a Symptomatic Slow-Acting Drug for Osteoarthritis (SADOA). This means it is designed for consistent use over several weeks or months before the full therapeutic benefit—reduced pain and improved function—becomes fully noticeable, differentiating it from faster-acting pain relievers.

Differentiation and Safety

The formulation containing Diacerein is clinically recognized for its unique anti-inflammatory properties that target joint tissue. However, regulatory bodies have placed restrictions on its use. This caution is primarily due to potential side effects related to the gastrointestinal tract and liver, especially in older patients or those with existing health conditions. Therefore, the use of Diacerein requires careful patient selection and adherence to the physician's prescribed regimen.

Note that some products marketed under variations of the name, such as “Dicon Plus,” contain a combination of ingredients like diclofenac (an NSAID) and paracetamol (acetaminophen) for more immediate, non-specific pain relief, serving a different clinical purpose.

What side effects are possible with Dicon?

Possible Side Effects and Safety Information

The official regulatory profile for Dicon (Diacerein) details adverse drug reactions primarily associated with the Gastrointestinal Disorders and Hepatobiliary Disorders system-organ classes. The most common effects are generally observed early in the course of treatment.

Frequency Classification Common Adverse Reactions
Very Common (> 1/10) Diarrhea, Abdominal pain
Common (1/100 to 1/10) Frequent bowel movements, Flatulence, Pruritus, Rash

The most frequent gastrointestinal effects typically start in the first weeks of treatment but tend to abate with continuing therapy. The documentation notes that dark urine may occur, which is related to the drug's composition and is without pathological significance.

Documented Serious Safety Concerns

The regulatory information highlights the potential for two main serious safety concerns: Hepatobiliary injury and complications from severe diarrhea. Cases of symptomatic acute hepatic injury, including hepatitis and hepatic failure, have been reported in the post-marketing phase, mostly occurring during the first months of treatment. Elevated hepatic enzymes in serum are classified as Uncommon.

Safety Restrictions and Special Populations

Official regulatory guidance imposes explicit restrictions on the use of diacerein. The medicine is contraindicated and must not be used in any patient with liver disease or a history of liver disease. Furthermore, its use is no longer recommended in patients aged 65 years and above due to the increased risk associated with severe diarrhea and subsequent complications.

Overdose and Emergency Response

Overdose and When to Seek Help for Dicon

An overdose with any medication, including Dicon, is a serious medical emergency that requires immediate professional assistance. The specific signs and symptoms of an overdose are dependent on the properties and concentration of the drug, but generally involve severe disruption of the body's key physiological systems.

Overdose risk is often associated with taking a higher dose than prescribed, accidental ingestion, or combining Dicon with other substances that affect the central nervous system. In cases of overdose, immediate intervention is critical to support vital functions and prevent potential long-term harm.

Key Symptoms of Severe Overdose

Symptoms that indicate a potential severe overdose requiring emergency attention can include:

  • Respiratory Distress: Significantly slowed, shallow, or labored breathing, or breathing cessation.
  • Central Nervous System Depression: Extreme drowsiness, inability to wake up or respond, or loss of consciousness.
  • Circulatory Changes: Slow or weak pulse, or signs of low blood pressure.
  • Other Manifestations: Pinpoint pupils, cold or clammy skin, or making gurgling or snoring sounds while unresponsive.

Emergency Protocol

Always seek emergency medical help immediately if an overdose is suspected. The specific management of a Dicon overdose focuses on supportive care for breathing and circulation, and may involve the administration of a known antidote, if one is available and applicable for the specific substance class. Patients at risk for an overdose, including those with household members at risk of accidental exposure, should discuss the availability and use of emergency reversal agents with their healthcare provider.

Therapeutic Uses of Dicon

What Dicon Treats: Main Uses and Benefits

Dicon (Diacerein) is commonly used for the symptomatic, long-term management of osteoarthritis (OA), relevant in contexts marked by increased discomfort and tension in the major joints, specifically the hip and knee. Its application is considered relevant in clinical settings where patients experience symptoms associated with this chronic joint disease.

The medication is commonly used to help with conditions presenting with systemic or localized discomfort, assisting with the symptoms related to physical discomfort and stiffness that may interfere with daily functioning. Its primary therapeutic role is to offer symptomatic relief that may assist with these manifestations and is relevant for easing the stiffness associated with functional impairment.

Quick Fact: Relief for Chronic Joint Pain and Stiffness

“It supports patients during episodes of heightened discomfort by helping to address the limited function and mobility of the affected joints.”

Dicon contributes to easing the overall symptom load during symptomatic periods and may assist with maintaining functional stability, relevant for supporting general well-being when symptoms become more noticeable.

Regulatory References

  1. European Medicines Agency referral document

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Dicon — Official Regulatory Information

The eligibility for Dicon (Diacerein) is subject to strict limitations defined by authoritative regulatory agencies, establishing specific groups who must not use the medicine and others for whom use is not recommended.

Eligibility Status Applicable Populations
Contraindicated (Must Not Use) Any patient with current or a history of liver disease. Individuals with known hypersensitivity to the drug or its components. Patients with inflammatory bowel disease or a history of functional diarrhea.
Allowed Under Standard Label Adults generally aged 18 to 64 years with no contraindicating comorbidities.

Regulatory Restrictions

  • Older Adults (65+): Use is not recommended in patients aged 65 years and above due to the increased risk of severe diarrhea and related complications.
  • Pediatric Use: The medicine is not recommended for use in children and adolescents under 18 years of age because safety and efficacy data are insufficient for this group.
  • Pregnancy and Lactation: Use is not recommended during pregnancy or while breastfeeding, as the active substance passes into breast milk and its safety profile is not fully established in these states.
  • Severe Renal Impairment: Patients with severe kidney dysfunction (creatinine clearance below 30 mL/min) are subject to use restrictions and require a mandatory dosage reduction.

The official eligibility structure heavily relies on these categorical exclusions and restrictions to limit the use of the medicine to a carefully selected adult population.

What should I know about interactions with other medicines?

Dicon Interactions with other medicines and products

Co-administration of Dicon with other medicinal products can alter its concentration in the body, primarily due to Dicon being a substrate for key metabolic enzymes and drug transporters. Official regulatory labeling requires specific precautions for co-use with agents that affect the metabolism or transport of Dicon.

Clinically Significant Interactions

Interacting Product Category Effect on Dicon Exposure Regulatory Constraint
Strong CYP3A4 Inducers (e.g., Rifampin, Phenytoin) Significantly decreased Restricted use or Contraindicated
Strong CYP3A4 Inhibitors (e.g., Ketoconazole, Clarithromycin) Significantly increased Use with Caution/Dose Adjustment
P-glycoprotein (P-gp) Inhibitors (e.g., Amiodarone) Increased Use with Caution/Monitoring
Gastric pH Modifiers (e.g., Antacids) Reduced Absorption Spacing requirement is mandatory

Co-administration with strong inducers of the CYP3A4 enzyme system is generally restricted or contraindicated, as this combination is documented to substantially decrease Dicon exposure, which may lead to a loss of efficacy. Conversely, concurrent use of strong CYP3A4 inhibitors results in increased Dicon systemic exposure, necessitating cautious co-use and the potential for clinical monitoring. The drug's absorption is dependent on gastric acidity; therefore, products that increase gastric pH require a specific timing separation from Dicon administration to prevent clinically relevant decreases in Dicon absorption.

Mechanism of Action

Diacerein is administered as a prodrug that exerts its action through its active metabolite, Rhein. Its mechanism is centered on modulating specific inflammatory and catabolic pathways within joint tissue, resulting in a slow, sustained modulation of the underlying catabolic pathway.


Targeting the Interleukin-1beta Catabolic Pathway

The primary mechanistic domain involves the selective inhibition of the Interleukin-1 beta ( IL-1beta) system . Rhein suppresses the synthesis and activity of this key pro-inflammatory cytokine and its related signaling components, particularly the transcription factor NF-kappaB. This action reduces the signaling** that promotes cartilage matrix breakdown by joint cells.


️ Modulating Enzyme and Matrix Homeostasis

The suppression of IL-1beta directly results in the downregulation of Matrix Metalloproteinases (MMPs). This effect is complemented by the simultaneous upregulation of growth factors, like TGF-beta, which stimulates the synthesis of structural components such as proteoglycans and Type II collagen. This dual mechanism modulates the physiological balance of the joint's extracellular matrix.


⏳ Constraint of Slow, Sustained Action

The observed physiological effects are inherently slow-onset because the mechanism relies on the gradual modulation of gene expression and protein synthesis rates within the cells, rather than rapid receptor blockade. This constraint means the mechanism’s physiological impact depends on the cumulative and sustained alteration of the catabolic pathway.

Dosage and Administration Information

How to Use Dicon

Dicon (Diacerein) is administered under a structured, long-term regimen that defines the use pattern. The medication is delivered via the oral route as a 50 mg hard capsule, intended for symptomatic management of osteoarthritis. Official guidance indicates that treatment be initiated by a specialist experienced in the management of this chronic condition.


Official Administration Schedule

The standard regimen involves a sequential, two-phase dosing strategy. This approach is intended to allow the body to adjust to the medication before reaching the full maintenance dose, consistent with the drug’s slow-acting profile.

Dosing Phase Dosage and Frequency Administration Timing
Initial Phase 50 mg once daily For the first two to four weeks of treatment
Maintenance Phase 50 mg twice daily (100 mg total daily) Thereafter, one capsule with breakfast and one with the evening meal

Key Usage Principles

Administration must be food-dependent; the capsules are required to be taken with meals. Furthermore, the instructions dictate that the capsules must be swallowed intact with a glass of water, and not opened or crushed. Due to the medication’s intended use as a Slow-Acting Drug for Osteoarthritis (SADOA), continuous administration over several weeks is required before the expected symptomatic effects are typically noted.

Standard guidance also provides parameters for specific populations. For patients with severe renal impairment (Creatinine Clearance less than 30 mL/min), the total daily dosage must be halved to 50 mg. Conversely, the use of Diacerein is generally not recommended for patients aged 65 years and older.

Recent Clinical Evidence

️ Research Evidence / Overview of Studies for Dicon

The body of research for Dicon (Diacerein) was conducted in patients with osteoarthritis (OA) to evaluate its long-term use, primarily involving the knee and hip joints. Official research evidence is derived from studies such as Randomized Controlled Trials (RCTs) and comprehensive meta-analyses that synthesize findings across multiple trials.


️ Evidence for Symptomatic Treatment of Osteoarthritis

Research examined whether Dicon use was associated with patterns of change in outcomes related to physical discomfort in patients with OA. Studies monitored how symptoms evolved in the observed populations and were designed to examine outcomes related to Dicon use against those of a placebo (an inactive pill).

Focusing on Measured Symptomatic Change

Studies explored the relationship between Dicon use and patient-reported outcomes describing perceived discomfort and functional activity level. Research monitored outcomes related to changes in pain intensity and functional limitations using standardized questionnaires. Studies reported measurements showing small differences in pain and function scores when comparing Dicon groups to the placebo group. Expert reviews note that the measured change may be often described as minimal, contributing to uncertainty regarding the clinical relevance.

Focusing on Structural and Disease Progression Studies

Studies also explored whether Dicon use was associated with patterns of change in the physical progression of the disease. This research primarily involved X-ray imaging to monitor changes in joint space width, a measure of cartilage deterioration. Some longer-term structural studies observed patterns where the rate of joint space narrowing was lower in study groups receiving Dicon compared to placebo, particularly in patients with hip OA. However, data show patterns related to structural changes that were less clear and inconsistent when studies focused on the knee joint.


Evidence Gaps and Areas of Uncertainty

The research highlights what is known—and what is still uncertain. The certainty remains low across several outcomes. Long-term effects are not fully established, and there is limited information for outcomes extending beyond the typical 1- to 3-year study periods. Furthermore, regulatory authorities have placed restrictions on use in older adults (aged 65 years and over), and the available data for certain groups, such as those with existing health conditions, remain insufficient. Research does not determine whether an individual will respond similarly, as study results reflect the specific conditions under which they were conducted.

Frequently Asked Questions (FAQ)

Common questions about Dicon (FAQ)


Q: Is Dicon the same type of medicine as [similar drug name]?

A: Dicon contains the active substance diacerein, which official documents classify as an anthraquinone derivative. Its purpose is to act as a Symptomatic Slow-Acting Drug for Osteoarthritis (SADOA). This classification indicates a mechanism that is distinct from fast-acting agents, such as common pain relievers or non-steroidal anti-inflammatory drugs (NSAIDs).


Q: Does Dicon interact with common vitamins or supplements?

A: Official drug information primarily details known interactions with other prescription medications, such as enzyme inhibitors and antacids. Regulatory documents do not specifically list common vitamins or supplements as known interacting agents. Patients typically find it helpful to review their full list of products, including vitamins and supplements, with their healthcare professional.


Q: Can Dicon affect my ability to drive?

A: Official regulatory warnings generally state that Dicon is not expected to affect the ability to drive or operate machinery. However, due to the possibility of experiencing side effects, official information suggests observing how the medicine affects one's reaction time and attention before operating machinery.


Q: What happens if I forget to take Dicon once?

A: The official administration instructions detail the correct dosing schedule. Specific, universal instructions for a single missed dose are not available in all product information. Regulatory guidance indicates that patients should not compensate for a missed dose by taking more than the prescribed amount at the next scheduled time.


Q: Are there any specific foods I should avoid while using Dicon?

A: No specific foods are listed as mandatory to avoid in the official product information for Dicon. However, administration instructions emphasize that the capsules must be taken with meals to ensure proper absorption.


Q: Why is Dicon not recommended for people with [specific health condition]?

A: The medicine is not recommended for certain populations, such as those with liver disease or inflammatory bowel conditions. This is due to documented safety risks including the potential for severe diarrhea and hepatobiliary (liver) injury, which are serious safety concerns noted in regulatory reports.


Q: Do older adults react differently to Dicon compared to younger people?

A: Yes, regulatory guidance states that the use of Dicon is not recommended in patients aged 65 years and over. This is because older adults face an increased risk of severe diarrhea and associated complications, leading to greater caution for this population.


Q: How does Dicon compare to similar non-prescription treatments?

A: Official research and regulatory reviews compare Dicon to inactive placebos and other treatments for osteoarthritis. Dicon is a prescription-only, slow-acting drug intended to modulate the disease pathway over time. This approach differs from the non-prescription, fast-acting pain relief offered by common over-the-counter remedies.


Q: Do common side effects of Dicon go away over time?

A: Yes, regulatory information indicates that the most common gastrointestinal effects, such as loose stools and diarrhea, typically start during the first weeks of treatment. These effects often tend to abate or decrease in frequency and severity with continued therapy.


Q: Is it normal to feel a mild headache when first starting Dicon?

A: Headache is not consistently listed as a very common or common side effect in official product information for Dicon alone. Side effect profiles summarize the reactions observed during clinical trials, and not all symptoms are noted in the most frequent categories.


Q: How long does Dicon stay in your system after stopping it?

A: The active metabolite of the drug has an elimination half-life of approximately 4.5 to 8 hours. However, the drug's intended action is slow and sustained, relying on the gradual modulation of processes within the joint cells rather than a rapid, short-term presence in the body.


Q: Can Dicon interact with herbal teas or natural remedies?

A: The active substance in Dicon is an anthraquinone derivative. Because other products containing anthraquinones (which can include certain herbal remedies) may increase the risk of gastrointestinal issues, caution is advised. It is generally advisable to discuss all herbal and natural remedies being used with a healthcare professional.


Q: Is Dicon used in children or teenagers?

A: No, Dicon is not recommended for use in children and adolescents under 18 years of age. This restriction is based on a lack of sufficient data concerning its safety and effectiveness in this younger age group, as noted in official regulatory guidance.


Q: Do different brands of Dicon contain the exact same ingredients?

A: All brands considered pharmaceutically equivalent must contain the exact same active ingredient (diacerein) in the identical strength. However, the inactive ingredients used in the capsule formulation—such as fillers and colorants—may differ between various manufacturers.


Q: What should I do if I suspect Dicon is causing a skin rash?

A: Official safety documents list rash as a common side effect. If symptoms such as a skin rash or any sign of hepatic injury are suspected, regulatory guidance states that treatment interruption is required, followed by immediate review by a healthcare professional.


Q: Can taking Dicon affect the results of a blood test?

A: Official safety information notes that an uncommon side effect is the potential for elevated hepatic enzymes (liver enzymes) in the serum. Due to the risk of liver injury, patients using Dicon are typically monitored for signs and symptoms of liver problems.


Q: Why is Dicon described as needing a prescription?

A: Dicon is classified as a prescription-only medicine (Rx) due to its overall safety profile. Its use requires careful patient selection and monitoring for specific risks, particularly liver problems and severe diarrhea, which necessitates administration under the guidance of a physician.


Q: Is there a risk of dependency or addiction with Dicon?

A: Dicon is classified as an anti-rheumatic agent. This class of medicine is not associated with dependency or addiction risk in regulatory documentation.


Q: Is Dicon effective for everyone who uses it?

A: Clinical trial results and expert reviews have noted that while the drug is associated with small reductions in pain, the measured symptomatic improvement is often described as minimal. Official documents reflect that the full therapeutic benefit may not be clinically significant for every individual who uses it.


Q: Why do some people say Dicon makes them feel tired?

A: Tiredness or fatigue is not consistently listed as a common or very common side effect of Dicon alone in official regulatory documents. Adverse reaction profiles summarize effects seen during studies, which sometimes include non-specific symptoms.


Q: Can Dicon be taken with common pain relievers like ibuprofen?

A: Regulatory information indicates that Dicon has a slow onset of action and may need to be combined with a faster-acting pain reliever or NSAID (such as ibuprofen) during the initial weeks of treatment. No known drug interaction with NSAIDs is typically listed as a mandatory constraint.


Q: Is there a maximum time Dicon is approved to be used?

A: Dicon is intended for the symptomatic long-term treatment of osteoarthritis. Regulatory documents describe a continuous administration regimen. While clinical studies often span several years, official guidance does not typically state a fixed maximum duration for use.


Q: Are there any specific tests needed before starting Dicon?

A: Due to the documented risk of liver injury, the medicine is contraindicated in any patient with liver disease. Official guidelines advise screening patients for liver problems, which often involves testing before treatment initiation to ensure patient suitability.


Q: What kind of patient monitoring is typically advised while using Dicon?

A: Regulatory bodies advise that patients be monitored for signs and symptoms of hepatic injury, especially during the first months of treatment. It is also important to monitor for severe diarrhea, which is a recognized risk associated with the medicine's use.


Q: What are the official sources for information about Dicon?

A: Authoritative, fact-based information about Dicon is found in government and intergovernmental documents. Key sources include the Summary of Product Characteristics (SmPC) from the European Medicines Agency (EMA) and the prescribing information published by national regulatory bodies.


Q: Are there different versions or strengths of Dicon?

A: The officially standardized use of Dicon is generally provided as 50 mg hard capsules. While the administration regimen may change over time, 50 mg is the standard strength for the single dosage form.

How should Dicon be stored and disposed of?

How to Store and Dispose of Dicon?

The official storage and disposal guidelines for Dicon (Diacerein) are mandatory to ensure the medication's stability and public safety, based on government regulatory labeling.


Storage Requirements

Condition Regulatory Rule
Environment Store in a cool, dry place and away from direct sunlight or excessive humidity.
Container Keep the container tightly closed and store in the original packaging.
Child Safety Must be kept out of the sight and reach of children, often advising to store locked up.

Disposal Instructions

Unused or expired Dicon must be discarded properly. Disposal of contents and container must be done in accordance with local, regional, and national regulations. To protect the environment, the product must not be thrown into wastewater or general household waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Dicon found in:

A-Z Index: